Probiotics are microorganisms that confer benefits on the host and, for this reason, have been proposed in various pathological states. Specifically, probiotic bacteria have been studied as a therapeutic option in patients with ulcerative colitis, but clinical results are mixed.
In particular, many probiotic species have been proposed with different therapeutic schemes, but no study has found probiotics in monotherapy in adequate trials for the induction of disease remission. Lactobacillus Rhamnosus GG (LGG) is a probiotic studied in depth and has ideal characteristics for use in patients with ulcerative colitis. The objective of the study was to investigate the clinical efficacy and safety of the administration of LGG in an open trial, administered as monotherapy at two different doses, in patients with mild-moderate severity ulcerative colitis.
